Please login to the form below

Not currently logged in
Email:
Password:

Ozempic

This page shows the latest Ozempic news and features for those working in and with pharma, biotech and healthcare.

News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched

News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched

It’s approved as Ozempic as a weekly injectable, but trials of its oral version are causing the most interest. ... In May Ozempic showed its superiority in a head-to-head with Trulicty on lowering blood sugar, and now new data from the SUSTAIN 7 trial

Latest news

  • The year of the blockbuster The year of the blockbuster

    Ozempic (semaglutide) from Novo Nordisk:Novo’s weekly GLP1 analogue was approved for use in patients with type 2 diabetes late last year and launched in February 2018. ... Despite competing in the crowded type 2 diabetes market, Ozempic is forecast to

  • Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1 Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

    Novo Nordisk fends off Lilly’ s GLP-1 challenge in Q1. Insulin specialist bounces back with encouraging signs from Ozempic launch. ... The majority of our sales districts are now switching promotional activities from Victoza to Ozempic, ”he added.

  • Novo Nordisk’s semaglutide obesity trial hits the mark Novo Nordisk’s semaglutide obesity trial hits the mark

    Daily injections could be a hard sell for patients struggling with being overweight, but Novo intends to take its new once-weekly subcutaneous formulation of semaglutide - approved as Ozempic by the ... Ozempic has not only outperformed Victoza in trials

  • Novo's oral semaglutide ‘safe and well-tolerated’ Novo's oral semaglutide ‘safe and well-tolerated’

    Novo Nordisk’s bid to bring an oral version of its new diabetes injectable Ozempic (semaglutide) to market has taken a step forward, with the release of its first late-stage ... Ozempic. That particular trial, SUSTAIN 7, saw Lilly’s blockbuster

  • Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

    EvaluatePharma has predicted Ozempic could become a $2.2bn product by 2022, while some other analysts believe it could do better and top $3bn at peak. ... Ozempic is also under review by the European Medicines Agency and the Japanese Pharmaceuticals and

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics